Prostaglandin E1 enhances safety of extracorporeal membrane oxygenation procedure

New drug molecule for treatment of atrial fibrillation
18 July 2022
Cardiac death rates declined for both Black and white Americans since 1999, but racial disparities persist
18 July 2022

Prostaglandin E1 enhances safety of extracorporeal membrane oxygenation procedure

In case of heart and/or lung failure, an ECMO machine can be used to maintain organ function for days or even weeks. Although extracorporeal membrane oxygenation (ECMO) technology has advanced, its use can still cause fatal complications in patients. In a recent study conducted with intensive care patients at University Hospital Vienna, MedUni Vienna researchers showed that the agent prostaglandin E1 could enhance the safety of the procedure. The study was published in the American Journal of Respiratory and Critical Care Medicine.

Comments are closed.